All categories

Metabolic signaling.

Incretin analogues and peptide signals studied in glucose regulation, appetite and energy metabolism.

8 source-linked dossiers. Categories organize research context, not approved uses or promised benefits. Evidence labels refer to the sources discussed in each record.

Reset filters

1–8 of 8 dossiers

Page 1 of 1

Evidence labels describe the cited sources, not a complete systematic review, a safety rating or regulatory approval. This archive does not yet cover every peptide.

Read the background

Amycretin (Zenagamtide): What the New Trials Actually Show

Amycretin, now also reported as zenagamtide, is an engineered molecule with GLP-1 and amylin receptor activity.

CagriSema vs Semaglutide: How to Read Combination Evidence

CagriSema research tests coadministered cagrilintide and semaglutide, not a new name for semaglutide alone.

Eloralintide: Selective Amylin Design and the 48-Week Trial

Eloralintide research links a molecular design question with a human weight-management question.

GLP-1 Weight Loss and Muscle Loss: What DXA Can Tell You

A headline about GLP-1 muscle loss may be describing a DXA estimate of lean tissue, the proportion of lost weight classified as lean, or a direct measure of strength.

Orforglipron: Why a GLP-1 Drug Does Not Have to Be a Peptide

Orforglipron activates the GLP-1 receptor, but it is a small molecule rather than a peptide. That distinction is useful because online discussions often use GLP-1, injectable and peptide as if they were the same classification.

Pemvidutide and MASH: Liver Endpoints Beyond Weight Loss

Pemvidutide’s IMPACT report separates two liver-biopsy questions: MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH.

Petrelintide: Reading the New Amylin Research

Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.

Retatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons

Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.

Semaglutide and Kidney Disease: What the FLOW Trial Found

FLOW studied adults with type 2 diabetes and chronic kidney disease. Its 24% lower hazard concerned a composite of major kidney events and kidney-related or cardiovascular death.

Semaglutide and Heart Outcomes: The SELECT Population Matters

SELECT tested a cardiovascular question in adults with established cardiovascular disease and overweight or obesity, without diabetes.

Semaglutide vs Tirzepatide: What Head-to-Head Evidence Shows

SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.

Weight Regain After Stopping Semaglutide: What STEP Studied

The often-quoted claim that people regain two-thirds of their weight loss after stopping semaglutide comes from a particular follow-up study.

Tirzepatide and MASH: What SYNERGY-NASH Can Establish

A liver-enzyme improvement, a reduction in liver fat and a change in biopsy-defined MASH describe different findings.

Tirzepatide and Sleep Apnea: What SURMOUNT-OSA Measured

Tirzepatide sleep-apnea research is strongest when the breathing measurement stays attached to the result.

GLP-1, GIP, Glucagon and Amylin Peptides Compared

GLP-1, GIP, glucagon and amylin name different signaling systems, not four interchangeable versions of one weight-loss peptide.

Tirzepatide and Hunger: Appetite, Cravings and Food Intake

Hunger, cravings and measured food intake can change together, but they are not the same outcome. Tirzepatide studies have used appetite questionnaires, a controlled meal and other experimental measures to investigate those differences.

Peptide Clinical Trial Endpoints: Read Beyond the Headline

A peptide trial can measure a hormone concentration, a symptom score, a change in weight and an adverse event in the same study.

Metabolic Peptides: Incretins & Energy Signaling | PeptideTwo